Patient-reported outcomes in cystic fibrosis

Christopher H. Goss, Alexandra Quittner

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Over the past 20 years, there has been tremendous progress in the area of patient-reported outcomes (PROs). A PRO instrument is defined as any measure of a patient's health status that is elicited directly from the patient and assesses how the patient "feels or functions with respect to his or her health condition." The advances seen in clinical research regarding PROs has been mirrored in research in cystic fibrosis (CF). A large number of instruments have been used for both therapeutic and nontherapeutic clinical research for many chronic conditions. This review will summarize a history of the development of PROs and how PROs are viewed by the U.S. Food and Drug Administration. We will then review the current state of the art of patient-reported outcomes in CF, specifically addressing the evaluation of different PRO instruments in terms of their reliability and validity. Finally, we will delineate further areas for development of PROs in CF. We believe that the future of CF research will incorporate a more diverse selection of PRO outcome measures; these outcomemeasures ultimately may be incorporated into clinical care to standardize symptom assessment and provide information regarding the need for specific clinical interventions to improve the quality of care delivered to these patients.

Original languageEnglish
Pages (from-to)378-386
Number of pages9
JournalProceedings of the American Thoracic Society
Volume4
Issue number4
DOIs
StatePublished - Aug 1 2007

Fingerprint

Cystic Fibrosis
Nontherapeutic Human Experimentation
Research
Patient Reported Outcome Measures
Symptom Assessment
Quality of Health Care
United States Food and Drug Administration
Reproducibility of Results
Health Status
Outcome Assessment (Health Care)
Health

Keywords

  • Instruments
  • Patient-reported outcomes
  • Quality of life
  • Symptoms
  • Validity

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology
  • Cell Biology

Cite this

Patient-reported outcomes in cystic fibrosis. / Goss, Christopher H.; Quittner, Alexandra.

In: Proceedings of the American Thoracic Society, Vol. 4, No. 4, 01.08.2007, p. 378-386.

Research output: Contribution to journalArticle

Goss, Christopher H. ; Quittner, Alexandra. / Patient-reported outcomes in cystic fibrosis. In: Proceedings of the American Thoracic Society. 2007 ; Vol. 4, No. 4. pp. 378-386.
@article{9990884a8c574f5b9a6499e664df7974,
title = "Patient-reported outcomes in cystic fibrosis",
abstract = "Over the past 20 years, there has been tremendous progress in the area of patient-reported outcomes (PROs). A PRO instrument is defined as any measure of a patient's health status that is elicited directly from the patient and assesses how the patient {"}feels or functions with respect to his or her health condition.{"} The advances seen in clinical research regarding PROs has been mirrored in research in cystic fibrosis (CF). A large number of instruments have been used for both therapeutic and nontherapeutic clinical research for many chronic conditions. This review will summarize a history of the development of PROs and how PROs are viewed by the U.S. Food and Drug Administration. We will then review the current state of the art of patient-reported outcomes in CF, specifically addressing the evaluation of different PRO instruments in terms of their reliability and validity. Finally, we will delineate further areas for development of PROs in CF. We believe that the future of CF research will incorporate a more diverse selection of PRO outcome measures; these outcomemeasures ultimately may be incorporated into clinical care to standardize symptom assessment and provide information regarding the need for specific clinical interventions to improve the quality of care delivered to these patients.",
keywords = "Instruments, Patient-reported outcomes, Quality of life, Symptoms, Validity",
author = "Goss, {Christopher H.} and Alexandra Quittner",
year = "2007",
month = "8",
day = "1",
doi = "10.1513/pats.200703-039BR",
language = "English",
volume = "4",
pages = "378--386",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "4",

}

TY - JOUR

T1 - Patient-reported outcomes in cystic fibrosis

AU - Goss, Christopher H.

AU - Quittner, Alexandra

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Over the past 20 years, there has been tremendous progress in the area of patient-reported outcomes (PROs). A PRO instrument is defined as any measure of a patient's health status that is elicited directly from the patient and assesses how the patient "feels or functions with respect to his or her health condition." The advances seen in clinical research regarding PROs has been mirrored in research in cystic fibrosis (CF). A large number of instruments have been used for both therapeutic and nontherapeutic clinical research for many chronic conditions. This review will summarize a history of the development of PROs and how PROs are viewed by the U.S. Food and Drug Administration. We will then review the current state of the art of patient-reported outcomes in CF, specifically addressing the evaluation of different PRO instruments in terms of their reliability and validity. Finally, we will delineate further areas for development of PROs in CF. We believe that the future of CF research will incorporate a more diverse selection of PRO outcome measures; these outcomemeasures ultimately may be incorporated into clinical care to standardize symptom assessment and provide information regarding the need for specific clinical interventions to improve the quality of care delivered to these patients.

AB - Over the past 20 years, there has been tremendous progress in the area of patient-reported outcomes (PROs). A PRO instrument is defined as any measure of a patient's health status that is elicited directly from the patient and assesses how the patient "feels or functions with respect to his or her health condition." The advances seen in clinical research regarding PROs has been mirrored in research in cystic fibrosis (CF). A large number of instruments have been used for both therapeutic and nontherapeutic clinical research for many chronic conditions. This review will summarize a history of the development of PROs and how PROs are viewed by the U.S. Food and Drug Administration. We will then review the current state of the art of patient-reported outcomes in CF, specifically addressing the evaluation of different PRO instruments in terms of their reliability and validity. Finally, we will delineate further areas for development of PROs in CF. We believe that the future of CF research will incorporate a more diverse selection of PRO outcome measures; these outcomemeasures ultimately may be incorporated into clinical care to standardize symptom assessment and provide information regarding the need for specific clinical interventions to improve the quality of care delivered to these patients.

KW - Instruments

KW - Patient-reported outcomes

KW - Quality of life

KW - Symptoms

KW - Validity

UR - http://www.scopus.com/inward/record.url?scp=34548255391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548255391&partnerID=8YFLogxK

U2 - 10.1513/pats.200703-039BR

DO - 10.1513/pats.200703-039BR

M3 - Article

C2 - 17652505

AN - SCOPUS:34548255391

VL - 4

SP - 378

EP - 386

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 4

ER -